FDA weighs esketamine for depression
Contact us: email@example.com
- FDA panels back intranasal esketamine for refractory depression.
- ONC aims to help doctors, patients with information sharing in proposed rule.
- Survey: Health care costs unlikely to improve in 2019.
- Vaccination and antiviral treatment don't lower stroke risk after shingles.
Download from Google Play
Download from App Store